Disclosed CapitolDisclosedCapitol
Home
Plans
Chad AI
API
Sign InGet Pro

Never Miss a Trade

Get weekly trade alerts free.

Explore

  • Politician Trades
  • Politicians
  • Executive Branch
  • Companies
  • All Stocks A–Z
  • Leaderboard
  • Compare Politicians
  • Committee Portfolios
  • Chad AI

Money & Policy

  • Government Contracts
  • Lobbying
  • Legislation
  • Campaign Finance
  • Institutional (13F)
  • Whale Watch (13D)

Markets

  • Markets Overview
  • Top Companies
  • Insider Trends
  • Economic Indicators
  • Live News

Resources

  • API Access
  • Developers
  • Developer Guides
  • Data Export
  • Glossary
  • Methodology
  • Data Sources
  • How It Works

Company

  • About Us
  • Press
  • FAQ
  • Pricing
  • vs. Capitol Trades
  • Contact
  • Watchlist

Legal

  • Editorial Standards
  • Corrections
  • Disclaimers
  • Privacy
  • Terms
© 2026 Disclosed Capitol. All rights reserved.
TermsPrivacyDisclaimer
HomeTrades
ChadWatchlistAccount

MRK

Healthcare
Merck & Co., Inc. · Drug Manufacturers - General
Trades
517
Politicians
0
Buys
261
Sells
237
Trades
517
Politicians
0
Buys
261
Sells
237
MRKvs S&P 500 (normalized)
|to
No price data available
MRK S&P 500 Buy Sell
Range
PoliticianActionDescriptionAmountTradedFiled
Maria Elvira SalazarR
SellMerck & Company, Inc. Common$1K - $15KSep 24, 2026Oct 7, 2026
Ro KhannaD
SellMERCK & CO INC. CMN$1K - $15KSep 4, 2026Oct 1, 2026
Michael McCaulR
SellMERCK &CO INC$50K - $100KAug 28, 2026Sep 5, 2026
Ro KhannaD
BuyMERCK & CO. INC. CMN$1K - $15KAug 24, 2026Sep 1, 2026
Maria Elvira SalazarR
BuyMerck & Company, Inc. Common$15K - $50KAug 19, 2026Sep 9, 2026
Maria Elvira SalazarR
BuyMerck & Company, Inc. Common$15K - $50KAug 19, 2026Sep 9, 2026
Ro KhannaD
BuyMERCK & CO INC. CMN$15K - $50KAug 7, 2026Sep 1, 2026
Ro KhannaD
SellMERCK & CO INC CMN$1K - $15KAug 3, 2026Sep 1, 2026
Ro KhannaD
BuyMERCK & CO., INC. CMN$1K - $15KJun 16, 2026Jul 1, 2026
Ro KhannaD
BuyMERCK & CO., INC. CMN$1K - $15KJun 2, 2026Jul 1, 2026
100 trades
…

Merck & Co., Inc. (MRK) Congressional Stock Trades

This page tracks congressional stock trading activity in Merck & Co., Inc. (MRK) in the Healthcare sector. Disclosed Capitol has indexed 517 disclosed congressional trades involving MRK. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.

As of October 2026 — Disclosed Capitol has tracked 517 disclosed congressional trades in Merck & Co., Inc. (MRK) — 261:237 buy-heavy ratio — led by Ro Khanna (D).

Which members of Congress trade Merck & Co., Inc.?

  • Ro Khanna (D) — 48 disclosed trades in MRK
  • Michael McCaul (R) — 12 disclosed trades in MRK
  • Gilbert Cisneros (D) — 8 disclosed trades in MRK
  • Julie Johnson (D) — 5 disclosed trades in MRK
  • Maria Elvira Salazar (R) — 3 disclosed trades in MRK

Recent MRK congressional trades

DatePoliticianPartyActionAmount
Sep 24, 2026Maria Elvira SalazarRSell$1,001 - $15,000
Sep 4, 2026Ro KhannaDSell$1,001 - $15,000
Aug 28, 2026Michael McCaulRSell$50,001 - $100,000
Aug 24, 2026Ro KhannaDBuy$1,001 - $15,000
Aug 19, 2026Maria Elvira SalazarRBuy$15,001 - $50,000
Aug 19, 2026Maria Elvira SalazarRBuy$15,001 - $50,000
Aug 7, 2026Ro KhannaDBuy$15,001 - $50,000
Aug 3, 2026Ro KhannaDSell$1,001 - $15,000
Jun 16, 2026Ro KhannaDBuy$1,001 - $15,000
Jun 2, 2026Ro KhannaDBuy$1,001 - $15,000

Buy vs. sell ratio & volume

Across the 517 disclosed congressional trades in Merck & Co., Inc. (MRK), members of Congress have reported 261 buys and 237 sells. The average 30-day alpha vs. the S&P 500 is -1.19%.

Merck & Co., Inc. financial snapshot (FY2025)

For fiscal year 2025, Merck & Co., Inc. reported revenue of $65.01B and net income of $18.25B, per SEC filings.

Revenue
$65.01B
Net income
$18.25B
Diluted EPS
$7.28
Net margin
28.1%
Free cash flow
$12.36B

Most recent reported quarter: Q2 FY2026 — revenue $16.61B, net income -$1.33B.

Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.